Skip to main content
SpringerLink
Log in

Increased risk of IV methotrexate AEs with concomitant febuxostat

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Mitsuboshi S, et al. Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat. Annals of Pharmacotherapy : 2 Nov 2021. Available from: URL: http://doi.org/10.1177/10600280211055794

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Increased risk of IV methotrexate AEs with concomitant febuxostat. Reactions Weekly 1881, 11 (2021). https://doi.org/10.1007/s40278-021-05220-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-05220-1

Search

Navigation